Clinical Trial Update: A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing two daclizumab dosing strategies to no induction therapy with tacrolimus, mycophenolate mofetil, and steroids to prevent acute allograft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transplant Rejection

Drugs mentioned

• Daclizumab (daclizumab)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Tacrolimus (Tacrolimus)
• steroids

Snippet

Sponsor: University of Cincinnati | Conditions: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients | Phase 4 | Status: COMPLETED